Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive — consensus is a manageable bar with non-GAAP EPS of ~$1.24 and revenue of ~$3.37B, and the biggest swing factor is whether value creation initiative G&A savings accelerate as promised and whether dental equipment momentum held through the quarter.

Heading into Q2 2026, Henry Schein's setup is modestly favorable: consensus non-GAAP EPS of $1.24 sits just above the $1.10 Q1 2025 comp and represents a reasonable bar given management's explicit guidance for G&A savings to accelerate in Q2 and more significantly in H2. Management's tone on the Q1 call was the most forward-looking and confident since the cyber incident — new CEO Fred Lowry reaffirmed full-year non-GAAP EPS guidance of $5.23–$5.37 and the $125M value creation run-rate target, and explicitly called out dental and equipment momentum continuing into May 2026. Estimate revisions have been stable-to-slightly-positive since the Q1 print, with the 2026FY EPS consensus essentially flat at ~$5.35, suggesting the Street is neither chasing the beat nor fading it — a neutral revision backdrop that leaves room for a positive surprise if value creation savings land ahead of schedule. The stock has rallied ~16% since the Q1 earnings date (vs. XLV +12%, SPY +5%), pricing in meaningful recovery but not yet a full re-rating to historical multiples, so the stock is not a crowded long. The key wildcard is intraoral scanner ASP pressure: ALGN's Q2 2026 results confirmed persistent softness in capital equipment and lower scanner ASPs from new low-cost entrants — a direct read-through to HSIC's digital equipment revenue line that could weigh on the equipment segment even if traditional equipment remains healthy.

KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar heading into Q2 2026 — non-GAAP EPS of $1.24 implies modest YoY growth and sits below the Q3/Q4 2025 run-rate, leaving room for upside if value creation savings accelerate. Non-GAAP EPS is the bigger swing factor; revenue consensus of $3.37B is a low bar relative to Q4 2025 actuals.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha consensus and actuals. All consensus figures as of August 3, 2026. Prior year period (Q2 2025) and Q1 2026 actuals from Visible Alpha reported figures.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Non-GAAP Diluted EPS

Total Revenue

Pattern: HSIC has beaten non-GAAP EPS in 6 of the last 8 quarters, with the two misses concentrated in the cyber-incident recovery period (Q2 2025 and Q4 2024). Revenue beats are more recent — the last three quarters have all come in above consensus after a string of misses during the cyber recovery. The EPS beat rate is strong and the bar for Q2 2026 looks achievable given the explicit guidance for accelerating G&A savings.

Guidance & Commentary Evolution

Key Takeaway: Full-year 2026 guidance is unchanged since the Q1 2026 earnings call — management reaffirmed non-GAAP EPS of $5.23–$5.37 and revenue growth of 3–5%. Tone has shifted more constructively with the new CEO emphasizing a performance culture and continuous improvement, and the July 30 leadership restructuring signals accelerating organizational simplification.

Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 2026 print — FY 2026 EPS consensus is essentially flat at ~$5.35 vs. the post-Q1 baseline of ~$5.35, suggesting the Street is tracking guidance rather than diverging. The gap between consensus and guidance midpoint is narrow, leaving limited cushion if Q2 misses but also no inflated bar to clear.

Source: Visible Alpha consensus as of May 10, 2026 (post-Q1 baseline) and August 3, 2026 (current). Guidance from Q1 2026 earnings call (May 5, 2026).

Estimates have barely moved since the Q1 print — the Street is essentially anchored to guidance. FY 2026 EPS consensus of $5.35 sits ~1% above the guidance midpoint of $5.30, implying the Street expects modest execution upside but is not pricing in a significant beat. The flat revision trajectory means Q2 results will be the primary catalyst for any estimate movement, with the value creation savings ramp being the key variable.

Stock Performance

Key Takeaway: HSIC has significantly outperformed both the healthcare sector (XLV) and the S&P 500 since the Q1 2026 earnings date, up ~16% vs. XLV +12% and SPY +5%, driven by a combination of multiple re-rating as the cyber-incident discount fades and improving earnings momentum from the value creation program — the stock is no longer a deep-value recovery play but has not yet reached historical multiple levels.

HSIC vs. XLV (Health Care Select Sector ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (May 5, 2026). Source: Yahoo Finance.

HSIC opened Q2 2026 with a modest post-earnings dip (stock fell ~7% in the first week after the May 5 print despite the beat, as the results were largely priced in), then steadily recovered through May and June as the market gained confidence in the value creation trajectory and dental market resilience. The stock broke out to new post-cyber highs in late June/early July, reaching ~$88 intraday before pulling back modestly. The July 30 leadership restructuring announcement (COO, Chief Strategy Officer, and SVP Global Supply Chain transitioning to advisory roles) was well-received as evidence of CEO Lowry's simplification agenda gaining traction. XLV has also outperformed SPY over the period, reflecting broader healthcare sector strength, but HSIC's outperformance of XLV by ~4 percentage points suggests company-specific re-rating rather than pure sector beta. The stock currently trades at approximately 16x NTM non-GAAP EPS, still below its pre-cyber historical average of ~18–20x, suggesting further re-rating potential if Q2 execution is clean.

Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the July 30 leadership restructuring — the elimination of the COO and Chief Strategy Officer roles and integration of supply chain into distribution is the clearest signal yet that CEO Lowry is moving decisively to simplify the operating model, which is a direct enabler of the value creation program and a positive read-through for Q2 and H2 execution.

• July 30, 2026 — Leadership Restructuring (8-K): Henry Schein announced that COO Michael Ettinger, Chief Strategy Officer Mark Mlotek, and SVP Global Supply Chain Jim Mullins will transition to senior advisory roles effective October 30, 2026. The company simultaneously created the Henry Schein Leadership Team (HSLT) to replace the Executive Management Committee and integrated the global supply chain organization with the global distribution group. CEO Lowry framed this as making the company "simpler, prioritize and make decisions faster, better execute on our priorities, and become an even more customer-centric organization."
• Implication: This is a significant structural change that accelerates the CEO's simplification agenda. Eliminating the COO layer and integrating supply chain with distribution directly supports the value creation program's cost efficiency targets. The market should view this positively as evidence of organizational agility and commitment to the $125M+ run-rate target.
• May 5, 2026 — Q1 2026 Earnings Beat & Guidance Reaffirmation: HSIC reported Q1 non-GAAP EPS of $1.32 (vs. consensus ~$1.21, a ~9% beat) and revenue of $3.37B (vs. consensus ~$3.34B). Full-year 2026 guidance reaffirmed at $5.23–$5.37 non-GAAP EPS and +3–5% revenue growth. Management explicitly called out dental and equipment momentum continuing into April and May 2026.
• Implication: Sets a positive tone for Q2 but the stock's muted reaction on the day (modest decline) suggests the beat was largely priced in. The guidance reaffirmation rather than raise was the key disappointment.
• May 5, 2026 — New Chairman Appointed: William K. ("Dan") Daniel was named independent Chairman of the Board as Stanley Bergman transitioned from the Chairman role. This completes the governance transition alongside the CEO change.
• Implication: Governance stabilization is a positive signal for institutional investors who had concerns about the concentration of power under the prior structure.
• Ongoing — E-Commerce Platform Rollout: Over 80% of U.S. dental e-commerce sales are now transacted on henryschein.com, with full U.S. rollout expected by end of August 2026, followed by international deployment. Canadian and U.S. laboratory customers have already been deployed.
• Implication: A completed U.S. rollout by end of Q2/early Q3 is a potential positive catalyst for customer engagement metrics and a differentiator vs. competitors.
• Ongoing — Tariff & Oil Price Mitigation: Management is actively mitigating rising oil price impacts on freight costs and product pricing using the same playbook as 2025 tariffs — redirecting customers to lower-cost or private-label alternatives and applying fuel surcharges. Q1 guidance assumes these impacts can be mitigated.
• Implication: If oil prices remain elevated or rise further, this could be a gross margin headwind in Q2 that management will need to address on the call.
• Ongoing — Value Creation Initiative Progress: Shared service center outsourcing partner appointed; indirect procurement savings beginning; gross profit initiatives (value pricing, corporate brand growth) underway. G&A savings were "nominal" in Q1 but explicitly guided to accelerate in Q2 and more significantly in H2.
• Implication: Q2 is the first quarter where value creation G&A savings should be visible in the P&L. Any quantification of the Q2 savings run-rate on the earnings call will be closely watched.

Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer commentary from Q1 2026 earnings calls (XRAY, NVST) and ALGN's Q2 2026 results (reported July 29, 2026) collectively confirm a stable-to-resilient dental market with DSO strength and equipment investment continuing, but flag a persistent headwind from intraoral scanner ASP compression from low-cost entrants — a direct negative read-through to HSIC's digital equipment revenue line heading into Q2.

Note: Only peer commentary from Q1 2026 earnings calls (reporting on Q1 2026 trends and Q2/FY 2026 outlook) and ALGN's Q2 2026 earnings call (reporting on Q2 2026 actuals) are included below. Prior-quarter results commentary has been excluded.

Align Technology (ALGN) — Q2 2026 Earnings (Reported July 29, 2026)

Read-Through Relevance: ALGN is the most direct and timely read-through for HSIC's Q2 2026 dental equipment segment, as ALGN's iTero scanner is a key product distributed through HSIC's network. ALGN reported Q2 2026 results just days before HSIC's expected print.

• Intraoral Scanner ASP Compression Continues — Negative Read-Through for HSIC Digital Equipment: ALGN reported Q2 2026 systems and services revenue of $185.3M, down 11% year-over-year, driven by "persistent softness in the capital equipment market" and a "shift toward lower-priced scanners and flexible acquisition models including leasing and rental programs, which generate lower upfront revenue than traditional scanner purchases." Scanner placements to new doctors reached a record level (up double digits YoY), but revenue declined sharply due to lower ASPs.
• HSIC Implication: This is a direct negative read-through for HSIC's digital equipment revenue in Q2 2026. HSIC management flagged this dynamic on the Q1 call ("lower average selling prices from new market entrants despite higher sales volume"), and ALGN's Q2 results confirm the trend has not abated. HSIC's digital equipment revenue line will likely face continued ASP headwinds in Q2, partially offset by volume growth.
• Dental Market Resilience Confirmed — Positive Read-Through: ALGN delivered record Q2 2026 revenues of $1.6B (+4.3% YoY) with record clear aligner volumes of 692,000 cases (+7.4% YoY). Growth was broad-based across orthodontists, GP dentists, and DSOs, and across adult, teen, and growing patient segments. A record 89,200 doctors globally submitted Invisalign cases (+3.4% YoY), and doctor utilization increased 3.8%.
• HSIC Implication: Strong aligner volumes and broad-based doctor engagement confirm the dental market is healthy and practitioners are investing in their practices. This is a positive read-through for HSIC's dental merchandise and specialty products segments.
• DSO Channel Strength — Positive Read-Through: ALGN noted "continued double-digit growth from DSO investments" and that "DSO businesses are very strong in North America overall." North America remained "relatively stable overall, with continued strength in orthodontic and DSO channels helping to offset slower retail demand."
• HSIC Implication: Consistent with HSIC management's Q1 commentary that DSOs are gaining market share in the overall dental market and that HSIC is benefiting from its strong position with national DSOs. Supports HSIC's dental merchandise and corporate brand growth thesis.
• Macro Backdrop — Mixed: ALGN described Q2 as "continued execution against a volatile macroeconomic backdrop" with "higher interest rates and increased macro uncertainty" weighing on capital equipment. However, international markets (APAC, EMEA, Latin America) showed strong double-digit volume growth. ALGN's forecasts "are not reflective of any kind of improvement in macro" — the company is executing despite the environment, not because of it.
• HSIC Implication: The macro environment is not a tailwind, but dental demand is proving resilient. HSIC's Q1 commentary that "dental markets remain stable and healthy" and that patient traffic is "stable to leaning positively" is consistent with ALGN's Q2 experience.
• FY 2026 Guidance Update — Systems & Services Revenue Lowered: ALGN now expects 2026 systems and services revenue growth to be down 6–8% YoY (vs. prior guidance), anticipating continued mix shift toward lower-priced scanners and flexible acquisition models in H2 2026. Itero scanner shipments are still expected to be up double digits YoY.
• HSIC Implication: ALGN's lowered systems revenue guidance for the full year signals that the ASP headwind is structural, not transitory. HSIC's digital equipment revenue will likely face continued pressure through H2 2026, though volume growth provides a partial offset.

Dentsply Sirona (XRAY) — Q1 2026 Earnings (Reported May 5, 2026)

Read-Through Relevance: XRAY is a major dental consumables and equipment manufacturer whose products are distributed through HSIC's network. XRAY's commentary on distributor dynamics, dental market demand, and equipment spending is a direct read-through for HSIC's dental distribution business.

• Underlying Dental Market Described as "Stable" — Positive Read-Through: XRAY stated that "the underlying market remains stable" despite near-term performance being affected by external pressures and investment timing. The company is "monitoring geopolitical and macro factors closely" but has not seen material impact.
• HSIC Implication: Consistent with HSIC's own Q1 commentary. A stable underlying market supports HSIC's dental merchandise volume assumptions for Q2.
• Distributor Inventory Levels Below Historical Averages — Neutral/Slightly Negative: XRAY noted that "U.S. distributor levels for CAD/CAM and imaging products remain below historical averages, a trend we expect to continue." The company also noted some "destocking of dealers" in consumables, particularly those that "may have gone into a little more PE-based" ownership.
• HSIC Implication: Below-average distributor inventory levels for CAD/CAM and imaging products could weigh on HSIC's equipment order intake in Q2. However, HSIC's own Q1 commentary indicated a healthy traditional equipment backlog, suggesting the destocking is more concentrated in digital/imaging categories.
• New Distributor Agreements Expanding — Positive for HSIC: XRAY announced an expanded agreement with Atlanta Dental Supply (its fourth new distributor agreement in 2026), adding its connected technology solutions portfolio effective August 1. Early traction includes Benco installing its first CEREC system ahead of schedule. XRAY noted the new drop-ship capital model is "well received" and "built into all of our agreements."
• HSIC Implication: XRAY's expansion of distributor relationships and the new drop-ship model for capital equipment could benefit HSIC as a key distribution partner. The Q2–Q4 inventory burn-through from the new model ($30M headwind previously guided for H1, now shifted to "late Q2 and H2") is a modest positive for HSIC's equipment revenue timing.
• DSO Activity Described as "A Lot of Great Activity" — Positive Read-Through: XRAY noted "a lot of great activity that is currently occurring with DSOs" and is targeting a "more active plan towards the second half of this year and into next year." The company views its broad portfolio as a "one-stop shop" for DSOs.
• HSIC Implication: Broad DSO investment activity is a positive read-through for HSIC's dental distribution volumes and corporate brand adoption, consistent with HSIC's own DSO wallet share expansion strategy.
• Freight/Oil Cost Headwinds Acknowledged — Neutral: XRAY noted "some headwinds with freight to oil" but stated "there's nothing that has occurred today that is material." The company reserved the right to update assumptions if the situation changes.
• HSIC Implication: Consistent with HSIC's own commentary on oil price mitigation. Both companies are managing the same input cost pressures, and neither has flagged a material impact to date.
• Q2 2026 Gross Margin Recovery Expected — Positive Sector Read-Through: XRAY guided for gross margins to "gain 300 basis points at a minimum back in the Q2, Q3 time frame" partly due to tariff adjustments from the SCOTUS decision (Trump 10% baseline).
• HSIC Implication: A sector-wide gross margin recovery in Q2 from tariff normalization is a positive read-through for HSIC's gross margin trajectory, supporting management's guidance for continued gross margin improvement.

Envista Holdings (NVST) — Q1 2026 Earnings (Reported May 6, 2026)

Read-Through Relevance: NVST is a dental products company (implants, orthodontics, diagnostics/imaging) whose products are distributed through HSIC's network. NVST's commentary on dental market resilience, imaging equipment demand, and implant trends is a read-through for HSIC's specialty products and equipment segments.

• Dental Market "Characteristic Resilience" Confirmed — Positive Read-Through: NVST posted 9.5% core growth in Q1 2026 (including a 4.5% billing day benefit), with the underlying business growing ~4% in line with expectations. Management stated that "the global dental market continued to demonstrate its characteristic resilience in Q1 even in the context of ongoing macro uncertainty." The market has "persistent excess demand over supply" that "propels dental as a category to outgrow the broader market essentially every single year."
• HSIC Implication: Strong confirmation of dental market health heading into Q2. NVST's broad-based growth across North America, Europe, and developing markets (ex-China VBP) supports HSIC's dental merchandise and specialty products volume assumptions.
• Imaging/Diagnostics Equipment Strength — Positive Read-Through: NVST's diagnostics business (DEXIS imaging systems) posted its "fourth straight quarter of positive growth" and was "particularly strong in developed markets." Equipment & Consumables segment grew nearly 12% in Q1. NVST cited software and AI-enabled solutions as key drivers of diagnostics demand.
• HSIC Implication: Strong imaging equipment demand from NVST is a positive read-through for HSIC's traditional and digital imaging equipment sales in Q2. This partially offsets the negative read-through from ALGN's scanner ASP compression.
• Implant Market — Developed Markets Strong, China Headwind: NVST reported implant core growth up low single digits overall, with "strong mid-single-digit to high single-digit growth in developed markets" (Europe and U.S.) offset by "strong double-digit declines in China" due to VBP channel inventory reduction. Nobel S Series new product launch showed "over 25% of orders coming from competitive conversions."
• HSIC Implication: Solid developed-market implant demand is a positive read-through for HSIC's Global Specialty Products segment (which includes BioHorizons implants). China VBP headwinds are less relevant for HSIC given its primarily U.S./international developed-market exposure.
• DSO Opportunity Highlighted — Positive Read-Through: NVST noted a "big opportunity" to gain share in DSOs for Spark aligners, referencing that a peer (implicitly ALGN) "does quite well with DSOs." This signals broad DSO investment activity across the dental sector.
• HSIC Implication: Broad DSO investment activity across multiple product categories (aligners, implants, imaging) is a positive read-through for HSIC's dental distribution volumes and DSO wallet share expansion strategy.
• Macro Uncertainty Acknowledged but Dental Proving Resilient: NVST noted that "Gulf events heating up in Q1" created macro uncertainty but that dental has "proven its resilience." The company estimated only a "mid-single-digit million dollar type of risk from fuel increases and related surcharges" — a manageable headwind.
• HSIC Implication: Consistent with HSIC's own macro commentary. The dental market's resilience to geopolitical and macro shocks is a structural positive for HSIC's distribution volumes.

Peer Read-Through Summary Table

Insider Transaction Activity

Key Takeaway: The only notable insider transaction since the Q1 2026 earnings date is a meaningful open-market purchase by Director William K. ("Dan") Daniel — who was simultaneously named Chairman of the Board — buying 10,000 shares on May 11, 2026, the day after the post-earnings dip. This is a constructive signal: a newly appointed Chairman buying stock in the open market at the post-earnings low is a meaningful vote of confidence in the company's trajectory.

Source: SEC Form 4 filing, filed May 12, 2026.

No other open-market buys or sells (Form 4 codes P/S) were identified for HSIC insiders in the period from May 5, 2026 through August 3, 2026. The absence of insider selling ahead of the Q2 print is a neutral-to-positive signal, particularly given the stock's ~16% appreciation since the Q1 earnings date. The Chairman's open-market purchase at the post-earnings dip is the most notable insider signal and is directionally constructive.